Brief: Centessa Pharmaceuticals Announces Dosing Of First Subject In Registrational Present-2 Study Evaluating Serpinpc For The Treatment Of Hemophilia B Without Inhibitors

Centessa Pharmaceuticals

10/07/2023 13:04

Centessa Pharmaceuticals PLC  260y.F :
    * CENTESSA PHARMACEUTICALS ANNOUNCES DOSING OF FIRST SUBJECT
IN
REGISTRATIONAL PRESENT-2 STUDY EVALUATING SERPINPC FOR THE
TREATMENT OF HEMOPHILIA B WITHOUT INHIBITORS
    * CENTESSA PHARMACEUTICALS: EXPECTS TO BEGIN DOSING IN
REGISTRATIONAL PRESENT-3 (AP-0103) STUDY FOR SUBJECTS WITH
HEMOPHILIA B WITH INHIBITORS THIS YEAR

Source text for Eikon:  ID:nGNXbzqP8Q 
Further company coverage:  260y.F